Gene

POLD1

DNA polymerase delta 1, catalytic subunit

Explore in graph →CI-GENE-00020325HGNC:9175 ENSG00000062822 NCBI 5424 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (7)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–7 of 7 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
POLD1 C284Y1
Pembrolizumab	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID4776 In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLD1 deleterious (as determined by Polyphen or SIFT) C284Y mutation and a high nonsynonymous mut…

Cohorts

Alteration frequency by cohort (84)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved84 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Endometrial Carcinoma MSI (MSK, Clin Cancer Res 2022) ucec_ccr_msk_2022	Endometrial Carcinoma	Ssm	47

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
· Science · 2015 · PMID 25765070 · validated civic_curation pubmed

POLD1 E374K1
Pembrolizumab	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	accepted	EID4777 In a retrospective study of 34 non-small cell lung cancer patients, a patient, who never smoked, with POLD1 deleterious E374K mutation (as determined by Polyphen or SIFT) and a high nonsynonymous muta… (full text at CIViC) PMID 25765070 · Rizvi et al., 2015 · Open in CIViC	civic

POLD1 E374K1

Pembrolizumab

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID4777

In a retrospective study of 34 non-small cell lung cancer patients, a patient, who never smoked, with POLD1 deleterious E374K mutation (as determined by Polyphen or SIFT) and a high nonsynonymous muta… (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

civic

POLD1 Loss4
ATR Inhibitor	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	4	submitted	EID13255 siRNA-mediated POLA1 protein depletion sensitized DLD-1 colorectal cancer cells to the ATR inhibitors ceralasertib (AZD6738) and berzosertib (VE-822), with approximately 9-fold and 4-fold shifts in IC… (full text at CIViC) PMID 39128273 · Schneider et al., 2024 · Open in CIViC	civic
〃	Malignant Pancreatic Neoplasm	Predictive	D	Supports Sensitivity Response	4	submitted	EID13257 siRNA-mediated POLA1 protein depletion sensitized PaTu8988t pancreatic cancer cells to the ATR inhibitors ceralasertib (AZD6738) and berzosertib (VE-822), producing approximately 7-fold and 6-fold IC5… (full text at CIViC) PMID 39128273 · Schneider et al., 2024 · Open in CIViC	civic
Chk1 Inhibitor	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	4	submitted	EID13256 siRNA-mediated POLA1 protein depletion sensitized DLD-1 colorectal cancer cells to the CHK1 inhibitors LY2603618 and MK-8776, producing approximately 6-fold and 8-fold shifts in IC50, respectively, re… (full text at CIViC) PMID 39128273 · Schneider et al., 2024 · Open in CIViC	civic
〃	Malignant Pancreatic Neoplasm	Predictive	D	Supports Sensitivity Response	4	submitted	EID13258 siRNA-mediated POLA1 protein depletion sensitized PaTu8988t pancreatic cancer cells to the CHK1 inhibitors LY2603618 and MK-8776, producing approximately 7-fold and 13-fold IC50 shifts, respectively, … (full text at CIViC) PMID 39128273 · Schneider et al., 2024 · Open in CIViC	civic

POLD1 Loss4

ATR Inhibitor

Malignant Colorectal NeoplasmCURATED_BROADER

Predictive

Supports Sensitivity Response

submitted

EID13255

siRNA-mediated POLA1 protein depletion sensitized DLD-1 colorectal cancer cells to the ATR inhibitors ceralasertib (AZD6738) and berzosertib (VE-822), with approximately 9-fold and 4-fold shifts in IC… (full text at CIViC)

PMID 39128273 · Schneider et al., 2024 · Open in CIViC

civic

〃

Malignant Pancreatic Neoplasm

Predictive

Supports Sensitivity Response

submitted

EID13257

siRNA-mediated POLA1 protein depletion sensitized PaTu8988t pancreatic cancer cells to the ATR inhibitors ceralasertib (AZD6738) and berzosertib (VE-822), producing approximately 7-fold and 6-fold IC5… (full text at CIViC)

PMID 39128273 · Schneider et al., 2024 · Open in CIViC

civic

Chk1 Inhibitor

Malignant Colorectal NeoplasmCURATED_BROADER

Predictive

Supports Sensitivity Response

submitted

EID13256

siRNA-mediated POLA1 protein depletion sensitized DLD-1 colorectal cancer cells to the CHK1 inhibitors LY2603618 and MK-8776, producing approximately 6-fold and 8-fold shifts in IC50, respectively, re… (full text at CIViC)

PMID 39128273 · Schneider et al., 2024 · Open in CIViC

civic

〃

Malignant Pancreatic Neoplasm

Predictive

Supports Sensitivity Response

submitted

EID13258

siRNA-mediated POLA1 protein depletion sensitized PaTu8988t pancreatic cancer cells to the CHK1 inhibitors LY2603618 and MK-8776, producing approximately 7-fold and 13-fold IC50 shifts, respectively, … (full text at CIViC)

PMID 39128273 · Schneider et al., 2024 · Open in CIViC

civic

POLD1 Y956N1
Pembrolizumab	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	—	submitted	EID4771 In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLD1 deleterious Y956N mutation (as determined by Polyphen or SIFT), treated with pembrolizumab … (full text at CIViC) PMID 25765070 · Rizvi et al., 2015 · Open in CIViC	civic

POLD1 Y956N1

Pembrolizumab

Lung Adenocarcinoma

Predictive

Supports Sensitivity Response

—

submitted

EID4771

In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLD1 deleterious Y956N mutation (as determined by Polyphen or SIFT), treated with pembrolizumab … (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

civic